Hip fractures are one of the leading causes of disability worldwide, and continue to grow in numbers given the aging global population. When hip fractures are repaired with open reduction, internal fixation, there is concern about the bone quality and healing potential in this population. Thus, numerous different therapies have been investigated recently in an effort to promote bone healing in this context. in this study, the authors evaluated the effects of romosozumab, a monoclonal antibody. The authors randomized patients to placebo or one of three doses of romosozumab. Overall, there was no important differences in Timed Up and Go Test, radiographic healing, Harris Hip Score or pain scores between any of the groups.